A L Taylor

Summary

Affiliation: University of Minnesota
Country: USA

Publications

  1. ncbi Should ethnicity serve as the basis for clinical trial design? Importance of race/ethnicity in clinical trials: lessons from the African-American Heart Failure Trial (A-HeFT), the African-American Study of Kidney Disease and Hypertension (AASK), and the A
    Anne L Taylor
    National Center of Excellence in Women s Health, University of Minnesota Medical School, Minneapolis, MN 55455, USA
    Circulation 112:3654-60; discussion 3666. 2005
  2. ncbi The African American Heart Failure Trial: a clinical trial update
    Anne L Taylor
    Division of Cardiology, University of Minnesota Medical School, Minneapolis, Minnesota 55455, USA
    Am J Cardiol 96:44-8. 2005
  3. ncbi Combination of isosorbide dinitrate and hydralazine in blacks with heart failure
    Anne L Taylor
    Department of Medicine Cardiology, University of Minnesota Medical School, Minneapolis 55455, USA
    N Engl J Med 351:2049-57. 2004
  4. ncbi Endothelial dysfunction and nitric oxide enhancing therapy: a new approach to the treatment of heart failure
    Anne L Taylor
    University of Minnesota Medical School, 420 Delaware Street S E, MMC 293, Minneapolis, MN 55455, USA
    Congest Heart Fail 10:237-42. 2004
  5. ncbi Outcomes by gender in the African-American Heart Failure Trial
    Anne L Taylor
    Department of Medicine, University of Minnesota, Minneapolis, Minnesota 55455, USA
    J Am Coll Cardiol 48:2263-7. 2006
  6. ncbi SERMs, ethnicity, and clinical trials: opportunities and challenges
    A L Taylor
    Division of Cardiology, Mayo Medical School, Minneapolis, Minnesota 55455, USA
    Ann N Y Acad Sci 949:292-4. 2001
  7. ncbi Early and sustained benefit on event-free survival and heart failure hospitalization from fixed-dose combination of isosorbide dinitrate/hydralazine: consistency across subgroups in the African-American Heart Failure Trial
    Anne L Taylor
    Department of Medicine, University of Minnesota, Minneapolis, MN 55455, USA
    Circulation 115:1747-53. 2007
  8. ncbi Isosorbide dinitrate and hydralazine in a fixed-dose combination produces further regression of left ventricular remodeling in a well-treated black population with heart failure: results from A-HeFT
    Jay N Cohn
    Cardiovascular Division, Department of Medicine, University of Minnesota, Minneapolis, Minnesota 55455, USA
    J Card Fail 13:331-9. 2007
  9. ncbi Ethnic differences in electrocardiographic criteria for left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint
    Peter M Okin
    Department of Medicine, Weill Medical College of Cornell University, New York, New York 10021, USA
    Am J Hypertens 15:663-71. 2002
  10. pmc Race and ethnicity in trials of antihypertensive therapy to prevent cardiovascular outcomes: a systematic review
    Ina U Park
    Department of Family Medicine and Community Health, University of Minnesota, Minneapolis, Minn, USA
    Ann Fam Med 5:444-52. 2007

Detail Information

Publications24

  1. ncbi Should ethnicity serve as the basis for clinical trial design? Importance of race/ethnicity in clinical trials: lessons from the African-American Heart Failure Trial (A-HeFT), the African-American Study of Kidney Disease and Hypertension (AASK), and the A
    Anne L Taylor
    National Center of Excellence in Women s Health, University of Minnesota Medical School, Minneapolis, MN 55455, USA
    Circulation 112:3654-60; discussion 3666. 2005
  2. ncbi The African American Heart Failure Trial: a clinical trial update
    Anne L Taylor
    Division of Cardiology, University of Minnesota Medical School, Minneapolis, Minnesota 55455, USA
    Am J Cardiol 96:44-8. 2005
    ..The rich and unique A-HeFT database will provide new opportunities to understand the pathophysiology and management of heart failure...
  3. ncbi Combination of isosorbide dinitrate and hydralazine in blacks with heart failure
    Anne L Taylor
    Department of Medicine Cardiology, University of Minnesota Medical School, Minneapolis 55455, USA
    N Engl J Med 351:2049-57. 2004
    ..We examined whether a fixed dose of both isosorbide dinitrate and hydralazine provides additional benefit in blacks with advanced heart failure, a subgroup previously noted to have a favorable response to this therapy...
  4. ncbi Endothelial dysfunction and nitric oxide enhancing therapy: a new approach to the treatment of heart failure
    Anne L Taylor
    University of Minnesota Medical School, 420 Delaware Street S E, MMC 293, Minneapolis, MN 55455, USA
    Congest Heart Fail 10:237-42. 2004
    ..The African-American Heart Failure Trial is the first prospective trial designed to test a novel therapy that enhances endothelial function and nitric oxide bioavailability in African-American patients with advanced heart failure...
  5. ncbi Outcomes by gender in the African-American Heart Failure Trial
    Anne L Taylor
    Department of Medicine, University of Minnesota, Minneapolis, Minnesota 55455, USA
    J Am Coll Cardiol 48:2263-7. 2006
    ..We therefore compared outcomes by gender and treatment...
  6. ncbi SERMs, ethnicity, and clinical trials: opportunities and challenges
    A L Taylor
    Division of Cardiology, Mayo Medical School, Minneapolis, Minnesota 55455, USA
    Ann N Y Acad Sci 949:292-4. 2001
    ....
  7. ncbi Early and sustained benefit on event-free survival and heart failure hospitalization from fixed-dose combination of isosorbide dinitrate/hydralazine: consistency across subgroups in the African-American Heart Failure Trial
    Anne L Taylor
    Department of Medicine, University of Minnesota, Minneapolis, MN 55455, USA
    Circulation 115:1747-53. 2007
    ....
  8. ncbi Isosorbide dinitrate and hydralazine in a fixed-dose combination produces further regression of left ventricular remodeling in a well-treated black population with heart failure: results from A-HeFT
    Jay N Cohn
    Cardiovascular Division, Department of Medicine, University of Minnesota, Minneapolis, Minnesota 55455, USA
    J Card Fail 13:331-9. 2007
    ..Whether the fixed-dose combination produces a further regression of LV remodeling when added to renin-angiotensin and sympathetic inhibitors has not been documented...
  9. ncbi Ethnic differences in electrocardiographic criteria for left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint
    Peter M Okin
    Department of Medicine, Weill Medical College of Cornell University, New York, New York 10021, USA
    Am J Hypertens 15:663-71. 2002
    ..However, the high mortality associated with LVH in African American patients makes more accurate ECG detection of LVH in these patients a clinical priority...
  10. pmc Race and ethnicity in trials of antihypertensive therapy to prevent cardiovascular outcomes: a systematic review
    Ina U Park
    Department of Family Medicine and Community Health, University of Minnesota, Minneapolis, Minn, USA
    Ann Fam Med 5:444-52. 2007
    ....
  11. ncbi Race-related differences in heart failure therapies: simply black and white or shades of grey?
    Gautam R Shroff
    Cardiovascular Division, University of Minnesota, MMC 508, 420 Delaware Street SE, Minneapolis, MN 55455, USA
    Curr Cardiol Rep 9:178-81. 2007
    ..This article explores the unique race-related differences in heart failure with particular emphasis on the currently recommended therapeutic agents in heart failure...
  12. ncbi Influence of blood pressure on the effectiveness of a fixed-dose combination of isosorbide dinitrate and hydralazine in the African-American Heart Failure Trial
    Inder S Anand
    VA Medical Center, Minneapolis, Minnesota, USA
    J Am Coll Cardiol 49:32-9. 2007
    ....
  13. ncbi Isosorbide dinitrate-hydralazine improves outcomes in African Americans with heart failure
    Monica Colvin-Adams
    Cardiac Transplantation, Department of Medicine, University of Minnesota, Minneapolis, MN 55455, USA
    Cleve Clin J Med 74:227-34. 2007
    ..This placebo-controlled trial was the first to evaluate a therapy in a specific racial group, and it points the way to a more individualized approach to heart failure therapy...
  14. pmc The African-American Heart Failure Trial: background, rationale and significance
    Anne L Taylor
    University of Minnesota, Minneapolis, USA
    J Natl Med Assoc 94:762-9. 2002
    ..Besides additional testing of H+ISDN in HF, A-HeFT will be the first HF trial aimed at a subgroup of African American patients, as well as the first to use a new composite HF score as its primary efficacy endpoint...
  15. doi Organizational climate and family life: how these factors affect the status of women faculty at one medical school
    S Lynn Shollen
    Office of Faculty Affairs, University of Minnesota Medical School, and Postsecondary Education Research Institute, University of Minnesota, Minneapolis, Minnesota 55455, USA
    Acad Med 84:87-94. 2009
    ..To compare men and women faculty's family situations and perceptions of organizational climate...
  16. ncbi Screening for early detection of cardiovascular disease in asymptomatic individuals
    Jay N Cohn
    Rasmussen Center for Cardiovascular Disease Prevention, Department of Medicine, University of Minnesota Medical School, Minneapolis, Minn, USA
    Am Heart J 146:679-85. 2003
    ..The objective of the current study is to screen individuals with vascular and cardiac tests aimed at identifying early abnormalities likely to progress and to measure risk contributors susceptible to therapy...
  17. ncbi The African-American Heart Failure Trial (A-HeFT): rationale and methodology
    Anne L Taylor
    University of Minnesota Medical School, Minneapolis, Minnesota 55455, USA
    J Card Fail 9:S216-9. 2003
  18. ncbi Exercise capacity in pediatric heart transplant candidates: is there any role for the 14 ml/kg/min guideline?
    B B Das
    Division of Cardiology, Department of Pediatrics, The Children s Hospital, University of Colorado Health Sciences Center, Denver, CO 80220, USA
    Pediatr Cardiol 27:226-9. 2006
    ..Because of age-related differences in oxygen consumption and varied etiologies of CHF a peak VO2 of < 14 ml/kg/min is not a useful criterion for listing for OHT in this population...
  19. ncbi Relationship between 24-H blood pressure and sleep disordered breathing in a normotensive community sample
    J T Wright
    Department of Medicine, Case Western Reserve University, Cleveland, Ohio 44106-4982, USA
    Am J Hypertens 14:743-8. 2001
    ..Further long-term evaluation of the effects of these findings and the long-term consequences of hypertension are needed...
  20. ncbi Aldosterone synthase promoter polymorphism predicts outcome in African Americans with heart failure: results from the A-HeFT Trial
    Dennis M McNamara
    University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA
    J Am Coll Cardiol 48:1277-82. 2006
    ..We sought to evaluate the effect of the aldosterone synthase promoter polymorphism on heart failure outcomes for subjects in the African American Heart Failure Trial (A-HeFT)...
  21. ncbi African-American Heart Failure Trial (A-HeFT): rationale, design, and methodology
    Joseph A Franciosa
    Zena and Michael A Wiener Cardiovascular Institute, Mt Sinai School of Medicine, New York, New York, USA
    J Card Fail 8:128-35. 2002
    ..Analysis of previous trials has shown that H+ISDN appears especially beneficial in African American patients...
  22. ncbi Effects of ACE inhibitors or beta-blockers in patients treated with the fixed-dose combination of isosorbide dinitrate/hydralazine in the African-American Heart Failure Trial
    Jalal K Ghali
    University Health Center, Wayne State University, Detroit, MI 48201, USA
    Am J Cardiovasc Drugs 7:373-80. 2007
    ....
  23. ncbi Evidence-based guidelines for cardiovascular disease prevention in women
    Lori Mosca
    J Am Coll Cardiol 43:900-21. 2004
  24. ncbi Evidence-based guidelines for cardiovascular disease prevention in women. American Heart Association scientific statement
    Lori Mosca
    Arterioscler Thromb Vasc Biol 24:e29-50. 2004

Research Grants1

  1. Univ of Minnesota Buidling Interdisciplinary Research Careers in Women's Health
    Nancy Raymond; Fiscal Year: 2007
    ..The BIRCWH program will enable us to capitalize on our strong environment and commitment to create the next generation of leaders in women's health research. ..